scholarly journals The role of metabotropic glutamate receptor 5 in the pathogenesis of mood disorders and addiction: combining preclinical evidence with human Positron Emission Tomography (PET) studies

2015 ◽  
Vol 9 ◽  
Author(s):  
Sylvia Terbeck ◽  
Funda Akkus ◽  
Laurence P. Chesterman ◽  
Gregor Hasler
Keyword(s):  
Positron Emission Tomography ◽  
Mood Disorders ◽  
Glutamate Receptor ◽  
Metabotropic Glutamate Receptor ◽  
Emission Tomography ◽  
Metabotropic Glutamate Receptor 5 ◽  
Metabotropic Glutamate ◽  
Positron Emission

scholarly journals Radiosynthesis and Evaluation of an18F-Labeled Positron Emission Tomography (PET) Radioligand for Metabotropic Glutamate Receptor Subtype 4 (mGlu4)

2014 ◽  
Vol 57 (21) ◽  
pp. 9130-9138 ◽  
Author(s):  
Kun-Eek Kil ◽  
Pekka Poutiainen ◽  
Zhaoda Zhang ◽  
Aijun Zhu ◽  
Ji-Kyung Choi ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Glutamate Receptor ◽  
Metabotropic Glutamate Receptor ◽  
Emission Tomography ◽  
Receptor Subtype ◽  
Metabotropic Glutamate ◽  
Positron Emission

Therapeutic Exploration of Metabotropic Glutamate Receptor Antagonists in Parkinson’s Disease by Positron Emission Tomography

US Neurology ◽  
2010 ◽  
Vol 05 (02) ◽  
pp. 21
Author(s):  
Rosario Sanchez-Pernaute ◽  
Anna-Liisa Brownell ◽  
◽  
Keyword(s):  
Positron Emission Tomography ◽  
Synaptic Plasticity ◽  
Metabotropic Glutamate Receptor ◽  
Mrna Translation ◽  
Synaptic Function ◽  
Emission Tomography ◽  
Metabotropic Glutamate ◽  
Positron Emission ◽  
Mglu5 Receptors

Metabotropic glutamate receptors (mGluR)s are G-protein-coupled receptors that function as modulators of synaptic function and glutamate transmission. Post-synaptically localized subtype 5 mGlu5 receptors are co-localized with adenosine A2a, dopamine, and N-methyl-D-aspartate (NMDA) receptors and regulate local protein synthesis and messenger RNA (mRNA) translation at synapses, and are thus ideally positioned to control synaptic plasticity. Aberrant synaptic plasticity appears to be involved in a number of developmental and degenerative neuropsychiatric disorders, including Parkinson’s disease. Pharmacological modulation of mGluR5 could potentially open new therapeutic avenues for the treatment of such disorders, for both symptomatic and neuroprotective purposes. In this review, we summarize a series ofin vivostudies we performed in order to delineate the anatomical basis and functional role of mGluR5 antagonists in Parkinson’s disease models, taking advantage of high-resolution positron emission tomography (PET) and the recent development of novel specific radiopharmaceuticals. Our findings of a prevalent distribution of mGluR5 in the striatum and limbic structures and a significant binding enhancement following dopamine lesions support the role of mGlu5 receptors in modulating dopamine- and glutamate-dependent signaling and synaptic plasticity within the basal ganglia cortico–subcortical loops.

Synthesis, radiolabeling, in vitro and in vivo evaluation of [18F]-FPECMO as a positron emission tomography radioligand for imaging the metabotropic glutamate receptor subtype 5

2009 ◽  
Vol 36 (6) ◽  
pp. 613-622 ◽  
Author(s):  
Christophe Lucatelli ◽  
Michael Honer ◽  
Jean-Frédéric Salazar ◽  
Tobias L. Ross ◽  
P. August Schubiger ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Glutamate Receptor ◽  
Metabotropic Glutamate Receptor ◽  
Emission Tomography ◽  
Receptor Subtype ◽  
In Vivo Evaluation ◽  
Metabotropic Glutamate ◽  
Positron Emission

Preclinical and the first clinical studies on [11C]ITMM for mapping metabotropic glutamate receptor subtype 1 by positron emission tomography

2013 ◽  
Vol 40 (2) ◽  
pp. 214-220 ◽  
Author(s):  
Jun Toyohara ◽  
Muneyuki Sakata ◽  
Masayuki Fujinaga ◽  
Tomoteru Yamasaki ◽  
Keiichi Oda ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Glutamate Receptor ◽  
Clinical Studies ◽  
Metabotropic Glutamate Receptor ◽  
Emission Tomography ◽  
Receptor Subtype ◽  
Metabotropic Glutamate ◽  
Positron Emission

scholarly journals In vivo variation in same-day estimates of metabotropic glutamate receptor subtype 5 binding using [11C]ABP688 and [18F]FPEB

2016 ◽  
Vol 37 (8) ◽  
pp. 2716-2727 ◽  
Author(s):  
Christine DeLorenzo ◽  
Jean-Dominique Gallezot ◽  
John Gardus ◽  
Jie Yang ◽  
Beata Planeta ◽  
...  
Keyword(s):  
Positron Emission Tomography ◽  
Glutamate Receptor ◽  
Metabotropic Glutamate Receptor ◽  
Emission Tomography ◽  
Receptor Subtype ◽  
Metabotropic Glutamate ◽  
Positron Emission ◽  
Absolute Test ◽  
Residual Radioactivity

Positron emission tomography tracers [11C]ABP688 and [18F]FPEB target the metabotropic glutamate receptor subtype 5 providing quantification of the brain glutamatergic system in vivo. Previous [11C]ABP688 positron emission tomography human test–retest studies indicate that, when performed on the same day, significant binding increases are observed; however, little deviation is reported when scans are >7 days apart. Due to the small cohorts examined previously (eight and five males, respectively), we aimed to replicate the same-day test–retest studies in a larger cohort including both males and females. Results confirmed large within-subject binding differences (ranging from −23% to 108%), suggesting that measurements are greatly affected by study design. We further investigated whether this phenomenon was specific to [11C]ABP688. Using [18F]FPEB and methodology that accounts for residual radioactivity from the test scan, four subjects were scanned twice on the same day. In these subjects, binding estimates increased between 5% and 39% between scans. Consistent with [11C]ABP688, mean absolute test–retest variability was previously reported as <12% when scans were >21 days apart. This replication study and pilot extension to [18F]FPEB suggest that observed within-day binding variation may be due to characteristics of mGluR5; for example, diurnal variation in mGluR5 may affect measurement of this receptor.

Sign in / Sign up

Export Citation Format

Share Document